The International Journal of Neuropsychopharmacology



Brief Report

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive–compulsive disorder: a double-blind cross-over study


Mendel Fux a1c1, Jonathan Benjamin a2 and R. H. Belmaker a1
a1 Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel
a2 Department of Psychiatry, Soroka Medical Center of the Kupat Holim Sick Fund, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel

Abstract

Current serotonin reuptake inhibitor (SRI) treatments for obsessive–compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale–Brown Obsessive–Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.

(Received January 17 1999)
(Reviewed April 26 1999)
(Revised June 8 1999)
(Accepted June 10 1999)


Key Words: Augmentation; inositol; obsessive–compulsive disorder; serotonin reuptake inhibitors.

Correspondence:
c1 Address for correspondence: Dr Mendel Fux, Beer-Sheva, Mental Health Center, PO Box 4600, Beer-Sheva, Israel. Tel.: (972 7) 640-1602 Fax: (972 7) 640-1621 E-mail: belmaker@bgumail.bgu.ac.il